Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 417

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 8
Chunk 417
---
 34,052 80,524 76,381 Total research and development expenses102,696 91,399 218,923 198,415 Personnel related general and administrative expenses20,115 17,105 38,853 36,190 Other general and administrative expenses12,152 8,089 22,767 14,240 Total general and administrative expenses32,267 25,194 61,620 50,430 Segment operating expenses134,963 116,593 280,543 248,845 Segment gain from divestiture of small molecule programs— — — 14,537 Segment loss from operations(134,963)(116,593)(280,543)(234,308)Segment interest and other income, net10,844 17,567 23,454 33,480 Segment loss before income taxes$(124,119)$(99,026)$(257,089)$(200,828)

There is no difference between the segment loss before income taxes and total consolidated loss before income taxes for the three and six months ended June 30, 2025 and 2024. 

21

ITEM 2.     MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q. This discussion and analysis and other parts of this report contain forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future financial performance that involve risks, uncertainties, and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts, and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the section titled “Risk Factors” included in this Quarterly Report on Form 10-Q.

Forward-looking statements include, but are not limited to, statements about:

•the progress, success, cost, and timing of our development activities, preclinical studies, and clinical trials, and in particular the development of our blood-brain barrier (“BBB”) platform, programs, and biomarkers, including the initiation and completion of studies or trials and related preparatory work, enrollment in such trials, the timing of when data from clinical